AI Discovers Natural Molecule That Halves Appetite Without Ozempic Side Effects

Stanford Medicine researchers have harnessed artificial intelligence to identify a naturally occurring molecule that dramatically suppresses appetite and promotes fat loss in animals, potentially offering a powerful alternative to Ozempic without the drug’s well-known digestive side effects. The molecule, called BRP, reduced food intake by up to 50 percent in laboratory animals and targeted a different brain pathway than existing weight-loss medications, raising hopes for a more precise approach to obesity treatment if future human trials prove successful.

How AI Transformed the Search for New Hormones

Finding new hormones has always been a needle-in-a-haystack problem. The human body produces enormous numbers of small protein fragments, but only a fraction carry important biological functions. Traditional approaches involve extracting proteins from tissues and analyzing them with mass spectrometry, a painstaking process complicated by the sheer volume of possible candidates.

The Stanford team, led by senior author Katrin Svensson, PhD, and senior research scientist Laetitia Coassolo, PhD, took a radically different approach. They built a computer algorithm called Peptide Predictor that analyzed approximately 20,000 human protein-encoding genes, searching for sequences where a specific enzyme called prohormone convertase 1/3 was likely to make cuts. This enzyme had previously been linked to human obesity and is responsible for producing GLP-1, the same hormone that semaglutide, Ozempic’s active ingredient, mimics.

The algorithm filtered candidates by focusing on genes associated with proteins released outside cells, a common characteristic of hormones, and requiring each candidate to contain at least four potential cutting sites. These criteria reduced the enormous pool of possibilities to 373 prohormones, making experimental testing far more practical. Peptide Predictor then estimated that the enzyme could produce 2,683 distinct peptides from those 373 proteins.

The algorithm was absolutely key to our findings, Svensson said. The research was published in the journal Nature.

A Tiny Peptide With a Surprising Punch

From the thousands of candidates, the researchers selected 100 peptides for laboratory testing, including GLP-1 as a benchmark. When applied to nerve cells grown in the laboratory, GLP-1 performed strongly, increasing neuronal activity to three times the level of untreated control cells.

One previously unrecognized peptide, however, produced an even more striking response. Consisting of just 12 amino acids, it increased neuronal activity tenfold compared with controls. The researchers named the molecule BRP, short for BRINP2-related-peptide, after the larger protein from which it originates.

That unusually powerful response made BRP a prime candidate for further investigation. The critical question was whether stimulating laboratory-grown brain cells would translate into meaningful changes in appetite and body weight in living animals.

Food Intake Drops by Half in Animal Studies

The team tested BRP in both lean mice and minipigs, which more closely mirror human metabolism and eating patterns than mice do. Before the animals were fed, researchers administered BRP through intramuscular injection.

The results were striking. During the hour following treatment, the animals consumed up to 50 percent less food than expected, demonstrating that BRP could strongly influence hunger in real time.

The scientists then examined whether repeated treatment could produce sustained weight changes. Obese mice received daily BRP injections for 14 days. By the end of the experiment, treated mice had lost an average of 3 grams, while untreated control mice had gained approximately 3 grams. Critically, nearly all the weight lost by BRP-treated mice came from body fat rather than muscle, a significant advantage for obesity treatment since muscle tissue supports strength, mobility, and metabolic health.

Treated animals also showed improvements in glucose tolerance and insulin sensitivity, indicators of how effectively the body handles sugar and responds to insulin.

A Different Brain Pathway With Fewer Side Effects

One of the most compelling aspects of the discovery is the possibility that BRP could deliver weight-loss benefits while avoiding unwanted effects associated with semaglutide and similar GLP-1 medications.

The receptors targeted by semaglutide are found throughout the body, including the brain, gut, pancreas, and other tissues. This broad distribution explains why Ozempic produces widespread effects such as slowing digestion, lowering blood sugar, and causing nausea and constipation in many patients.

BRP, in contrast, appears to act specifically in the hypothalamus, the small but essential region deep within the brain that regulates hunger, energy use, body temperature, and internal balance. By activating different populations of brain cells than semaglutide, BRP may make it possible to control hunger more precisely while reducing unwanted effects elsewhere in the body.

To investigate potential side effects, researchers monitored the behavior and physical responses of treated mice and pigs. They found no significant differences in movement, water consumption, anxiety-related behavior, or fecal output compared with control animals. The absence of changes in fecal production was particularly notable because constipation is a well-known side effect of GLP-1 medications. The experiments also showed that BRP promoted fat loss without the substantial muscle loss that can accompany some weight-reduction treatments.

What Comes Next for the Natural Ozempic Alternative

Despite the encouraging findings, BRP remains at an early stage of development. Several critical questions must be answered before it could become a practical treatment.

• Receptor identification: Researchers need to identify which cell surface receptors recognize BRP, which would help explain its effects on hunger and metabolism.
• Duration of activity: Peptides can be broken down relatively quickly in the body, potentially requiring frequent injections. A longer-lasting version of BRP would make treatment more convenient.
• Human safety trials: Clinical trials must evaluate BRP’s safety, effectiveness, appropriate dosage, and side effect profile in people before it could become available.
• Long-term effects: Researchers need to understand how the molecule communicates with cells and whether its effects can be sustained over extended periods.

Svensson has cofounded a company called Merrifield Therapeutics to advance BRP toward human clinical trials. Both Svensson and Coassolo are named inventors on patents involving the use of BRP peptides to treat metabolic disorders.

The lack of effective drugs to treat obesity in humans has been a problem for decades, Svensson noted. Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans.

The Broader Implications for Obesity Treatment

The discovery of BRP highlights how artificial intelligence is reshaping medical research. By using computational tools to search through thousands of potential biological compounds, scientists can identify promising candidates far more efficiently than traditional laboratory methods allow. The Peptide Predictor algorithm reduced a universe of hundreds of thousands of possible peptides to a manageable set of 100 for testing, demonstrating how AI can accelerate drug discovery.

Obesity affects hundreds of millions of people worldwide and is linked to heart disease, diabetes, certain cancers, and other serious health conditions. While GLP-1 medications like Ozempic, Wegovy, and Mounjaro have transformed obesity treatment in recent years, their side effects, cost, and the need for ongoing injections have driven demand for alternatives.

If BRP proves effective in human trials, it could offer a new option for patients who struggle with GLP-1 side effects or who prefer a treatment that targets appetite more selectively. The fact that it works through a non-incretin pathway, meaning it does not rely on the same hormone system as GLP-1 drugs, makes it a genuinely novel approach rather than a variation on existing therapies.

Research collaborators included scientists from the University of California, Berkeley; the University of Minnesota; and the University of British Columbia. Financial support came from the National Institutes of Health, the SPARK Translational Research Program at Stanford, Stanford Bio-X, the Stanford Maternal and Child Health Research Institute, the American Heart Association, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance.

While it will likely be years before BRP could reach patients, the discovery represents a significant step forward in the search for safer, more targeted obesity treatments. The combination of AI-driven discovery and novel biological mechanisms may well define the next generation of weight-loss therapeutics, offering hope to millions seeking effective treatment without debilitating side effects.

---

Edited by Palawan @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous